Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ixazomib + lenalidomide + dexamethasone for MRD assessment in newly diagnosed transplant-eligible multiple myeloma
2024-517321-99-00Phase 2Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of ixazomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Helsinki University Hospital. Primary endpoint: Undetectable flow MRD rate. Planned start Aug 2016; status: authorised.
02
Drugs
ixazomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517321-99-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517321-99-00.